Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) is currently trading at $318.85. The stock has a 52-week range of $224.32 to $491.22 and a market capitalization of $42.29B.

Alnylam Pharmaceuticals, Inc. has a P/E ratio of 136.8 (forward P/E: 22.4), a dividend yield of none, and 1-year performance of +21.6%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.

There have been 318 insider transactions for ALNY in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.

Alnylam Pharmaceuticals, Inc. (ALNY) has returned +21.6% over the past 12 months. The stock traded between $224.32 and $491.22 during this period, and is currently at $318.85.

2 tracked hedge funds currently hold ALNY in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.

Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalization of $42.29B. The trailing P/E ratio is 136.8 and forward P/E is 22.4. The stock is classified in the Healthcare sector.

Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B with net income of $313.75M and a profit margin of 0.08%. The stock has a beta of 0.38.

Alnylam Pharmaceuticals, Inc. (ALNY) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.